| ²é¿´: 4040 | »Ø¸´: 16 | ||||
| µ±Ç°Ö»ÏÔʾÂú×ãÖ¸¶¨Ìõ¼þµÄ»ØÌû£¬µã»÷ÕâÀï²é¿´±¾»°ÌâµÄËùÓлØÌû | ||||
wachinaÖÁ×ðľ³æ (ÖªÃû×÷¼Ò)
|
[½»Á÷]
ÎäÌïfasiglifam (TAK-875)Ðû¸æÊ§°Ü£¬ºãÈðß»¸ñÁзº³ÝÍö´½º® ÒÑÓÐ16È˲ÎÓë
|
|||
|
Takeda terminates development activities for fasiglifam (TAK-875) Takeda Pharmaceutical Company Limited (Takeda) announced that it has decided voluntarily to terminate the development activities for fasiglifam (TAK-875), an investigational treatment for type 2 diabetes, due to concerns about liver safety. Patient safety is Takeda's highest priority. The company has worked with three independent panels of experts to provide for the safety of trial participants and ensure independent safety oversight for the clinical trials throughout the duration of the fasiglifam (TAK-875) Phase 3 development program. The expert panels include the independent Data Monitoring Committee (DMC), a committee that oversees the fasiglifam global clinical development program, reviews the unblinded clinical data from program trials and provides continual safety oversight of trial subjects and recommendations. The DMC is comprised of clinical experts in endocrinology, cardiology and hepatology as well as a statistician. The independent Liver Safety Evaluation Committee (LSEC) is comprised of five hepatologists with expertise in drug-induced liver injury. While remaining blinded to treatment information, the LSEC regularly evaluates data on liver enzymes elevations and adjudicates cases that impacted the liver. In addition, an independent Executive Committee (EC) provides additional oversight for the fasiglifam (TAK-875) cardiovascular outcomes trial. After careful consideration of the data emerging from all the clinical trials and in consultation with these panels, the company has reached the conclusion that, on balance, the benefits of treating patients with fasiglifam (TAK-875) do not outweigh the potential risks. For this reason, Takeda has decided voluntarily to terminate the development activities for fasiglifam. ×÷ΪÂýÐÔ¼²²¡£ºÌÇÄò²¡µÄÖÎÁÆ£¬¸Î¶¾ÐÔÌ«ÖÂÃüÁË£¬ÄѹÖÎäÌï»ÓÀáÕ¶ÂíÚÕ¡£ÖµµÃÒ»ÌáµÄÊÇ£¬ºãÈðÒ²ÏòCFDAÉ걨ÁËGPR-40¼¤¶¯¼Áß»¸ñÁзº£¬ÏÖÔÚÐÄÀï¹À¼ÆÒ²ÊǰÎÁ¹°ÎÁ¹µÄ |
» ÊÕ¼±¾ÌûµÄÌÔÌûר¼ÍƼö
ÐÂÒ©·ÂÒ© |
» ²ÂÄãϲ»¶
ÈçºÎÖÆ±¸·ûºÏ¼¼ÊõÒªÇóµÄÒ©Æ·±ê׼Ʒ£¿
ÒѾÓÐ0È˻ظ´
¶ÔÕÕÆ·ÔÚÒ©Æ·Ñз¢ÖеIJ»¿É»òȱÐÔ
ÒѾÓÐ0È˻ظ´
Ò©ÀíѧÂÛÎÄÈóÉ«/·ÒëÔõôÊÕ·Ñ?
ÒѾÓÐ151È˻ظ´
±ê׼ƷµÄ·ÖÀàºÍÓÃ;£¬ÄãÖªµÀ¶àÉÙ£¿
ÒѾÓÐ0È˻ظ´
ÔÓÖʶÔÕÕÆ·¼Û¸ñÈçºÎ½ç¶¨ºÍÕýȷʹÓ÷½·¨
ÒѾÓÐ0È˻ظ´
ÔÑÐÖÆ¼Á¡¢·ÂÖÆÒ©£ºÔÓÖʶÔÕÕÆ·ÔÚÒ©Æ·Éú²úÖеÄÓ¦ÓÃ
ÒѾÓÐ0È˻ظ´
ÔÑÐÖÆ¼Á¡¢·ÂÖÆÒ©£ºÔÓÖʶÔÕÕÆ·ÔÚÒ©Æ·Éú²úÖеÄÓ¦ÓÃ
ÒѾÓÐ0È˻ظ´
±ê׼ƷÔÚÉú²ú¹ý³ÌÖеÄÖØÒªÐÔºÍÓ¦ÓÃʵÀý
ÒѾÓÐ0È˻ظ´
ßÁ¶ßËØÔÓÖÊ
ÒѾÓÐ0È˻ظ´
Ë«ÑÎËáÌæÂå¡🚀 ¸ß´¿Îȶ¨・ͼÆ×ÍêÕû ¿¹²¡¶¾Ò©Ñз¢Ò»²½µ½Î»
ÒѾÓÐ0È˻ظ´
wph75623
ͳæ (СÓÐÃûÆø)
- Ó¦Öú: 1 (Ó×¶ùÔ°)
- ½ð±Ò: 159.9
- Ìû×Ó: 137
- ÔÚÏß: 54.9Сʱ
- ³æºÅ: 1922830
- ×¢²á: 2012-08-03
- רҵ: ºÏ³ÉÒ©Îﻯѧ
¡ï
Сľ³æ: ½ð±Ò+0.5, ¸ø¸öºì°ü£¬Ð»Ð»»ØÌû
Сľ³æ: ½ð±Ò+0.5, ¸ø¸öºì°ü£¬Ð»Ð»»ØÌû
| ÌÇÄò²¡ÈçºÎÖÎÁÆ£¬²¡ÒòÈçºÎ£¬ÈÔÊÇδ֪µÄ£¬ÕâÑùµÄ´úлÎÉÂÒ¼²²¡ÆäʵÊÇ»úÌåÄÚÔ๦ÄÜʧµ÷µÄ±íÏÖ£¬Ä¿Ç°Î÷Ò©¶¼ÊÇÖα겻Öα¾£¬Ñо¿ÄÜÖÎÓú¸Ã¼²²¡µÄÒ©Îï²ÅÊÇÖÕ¼«Ä¿±ê£¬ÏÖÔÚµÄÒ©¶¼ÊÇÔÚ³¸ö°ÐµãµÄ¸ÅÄ¶Ô»¼ÕßÄÑÓÐʵÔÚµÄÒæ´¦ |
4Â¥2013-12-30 16:49:55
jinshanshi88
ľ³æ (ÖøÃûдÊÖ)
- Ó¦Öú: 5 (Ó×¶ùÔ°)
- ½ð±Ò: 2359.2
- Ìû×Ó: 1236
- ÔÚÏß: 259.3Сʱ
- ³æºÅ: 453008
- ×¢²á: 2007-11-06
2Â¥2013-12-30 12:41:43
guri
Ìú³æ (³õÈëÎÄ̳)
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 74
- Ìû×Ó: 6
- ÔÚÏß: 9.6Сʱ
- ³æºÅ: 2285814
- ×¢²á: 2013-02-18
- ÐÔ±ð: GG
- רҵ: Ò©ÎïÉè¼ÆÓëÒ©ÎïÐÅÏ¢
¡ï
Сľ³æ: ½ð±Ò+0.5, ¸ø¸öºì°ü£¬Ð»Ð»»ØÌû
Сľ³æ: ½ð±Ò+0.5, ¸ø¸öºì°ü£¬Ð»Ð»»ØÌû
| ß»¸ñÁзºÖ»ÊǺãÈð¹ÜÏßÖеÄÒ»¸öÁÙ´²»¯ºÏÎӦ¸Ã¿ÉÒÔ¸îÉáµô¡£µ¹ÊÇÕû¸öÌÇÄò²¡ÁìÓò¾Íû¿´µ½ÕæÕýºÃµÄае㣬ÕâÊǷdz£ÖµµÃÓÇÂǵġ£¡£¡£ |
3Â¥2013-12-30 13:06:43
| °¥£¡£¡£¡£¡£¡£¡£¡ |
5Â¥2013-12-30 17:02:55













»Ø¸´´ËÂ¥
5